RECURSION PHARMACEUTICALS, INC. Quarterly Nonoperating Income (Expense) in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Recursion Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2020 to Q3 2024.
  • Recursion Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $2.68M, a 59% decline year-over-year.
  • Recursion Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $11.2M, a 36.1% decline year-over-year.
  • Recursion Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $17.9M, a 187% increase from 2022.
  • Recursion Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $6.25M.
  • Recursion Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$3.7M, a 54.9% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $11.2M $2.68M -$3.85M -59% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $15.1M $2.48M -$2.51M -50.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $17.6M $4.19M -$350K -7.71% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $17.9M $1.87M +$380K +25.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $17.6M $6.53M +$4.41M +207% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $13.1M $4.99M +$4.36M +691% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $8.79M $4.54M +$2.54M +127% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $6.25M $1.49M +$1.47M +5426% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 $4.79M $2.13M +$3.15M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $1.63M $631K +$3.1M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$1.47M $2M +$2.23M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$3.7M $27K +$212K Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$3.92M -$1.03M +$373K +26.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$4.29M -$2.47M -$1.75M -240% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$2.54M -$233K -$152K -188% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$2.39M -$185K Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 -$1.4M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$726K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$81K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.